Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2008, 44(9): 653
ISSN 1699-3993
Copyright 2008 Clarivate Analytics
CCC: 1699-3993
DOI: 10.1358/dot.2008.44.9.1256003
 
 
Milnacipran hydrochloride: Its efficacy, safety and tolerability profile in fibromyalgia syndrome
Owen, R.T.
 
 
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI), although its norepinephrine reuptake inhibition predominates. It has been marketed in Europe and Japan as an antidepressant for many years, but only recently has it been investigated as a treatment for fibromyalgia syndrome (FMS). Both open-label and doubleblind, placebo-controlled trials have confirmed its efficacy in FMS, not only on the pain component but also on the fluctuating array of other symptoms such as sleep and cognitive disturbances and fatigue The phase III trials have employed comprehensive composite endpoints to more accurately capture the many complex domains of FMS. Milnacipran's efficacy was not limited to the shortterm, 12-week trials. It also demonstrated durability of response for up to 1 year. Its safety and tolerability were typical of its class, and it was generally well tolerated. Further work will be required to establish its place in FMS therapy by comparing it directly with other agents.


Full Text: HTMLPDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy